48 results on '"Baggstrom, Maria Q."'
Search Results
2. Racialized economic segregation and treatment and outcomes of small-cell lung cancer
3. Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer
4. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
5. Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies
6. Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy
7. Prevalence of Women in Medicine Programs at University-Based Internal Medicine Residency Programs.
8. Pulsatile Erlotinib in EGFR-Positive Non–Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature
9. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)
10. Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution (Preprint)
11. Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
12. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial
13. Lung Cancer in Older Adults
14. A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104
15. A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations
16. The Effect of FDG-PET on the Stage Distribution of Non-small Cell Lung Cancer
17. Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis
18. Aplasies médullaires
19. Contributeurs
20. Contributors
21. Bone Marrow Failure States
22. A Phase II Study of AT-101 (Gossypol) in Chemotherapy-Sensitive Recurrent Extensive-Stage Small Cell Lung Cancer
23. Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: Focus on Non-small Cell Lung Cancer (2010)
24. Barriers to Enrollment in Non-small Cell Lung Cancer Therapeutic Clinical Trials
25. Radiotherapy
26. Distinctive Characteristics of Non-small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis
27. Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis
28. Efficacy of Vinorelbine in the Second-Line Setting and Beyond in Non-small Cell Lung Cancer
29. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer
30. Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC
31. The role of surgery in stage III non-small-cell lung cancer
32. Delayed nausea and vomiting from carboplatin doublet chemotherapy
33. A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer
34. Postoperative Radiotherapy for Pathologic N2 Non–Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: A Review of the National Cancer Data Base
35. 72 - Aplasies médullaires
36. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis [2]
37. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
38. A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors
39. A Phase I trial of weekly docetaxel and topotecan for solid tumors
40. A Phase I Study of Bexarotene and Rosiglitazone in Patients with Refractory Cancers
41. A Phase I Study of Docetaxel and Bexarotene
42. P1-250: Barriers for accrual to clinical trials in adult patients (pts) with non-small cell lung cancer
43. Drug delivery and toxicity of adjuvant chemotherapy for non-small cell lung cancer (NSCLC): Washington University experience
44. O-234 The role of singlet (1CR) vs. doublet (2CR) vs. triplet (3CR) chemotherapy regimens in stage IIIB/IV non-small lung cancer (NSCLC): A meta-analysis of the published literature
45. A Phase I trial of weekly docetaxel and topotecan for solid tumors.
46. Barriers for accrual to clinical trials in adult patients (pts) with non-small cell lung cancer.
47. Investing in Women Trainees: Building a Women in Medicine Group at an Academic Institution.
48. Duration of therapy in advanced, metastatic non-small-cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.